Repozitorij Univerze v Novi Gorici

Izpis gradiva
A+ | A- | Pomoč | SLO | ENG

Naslov:Ex vivo drug response heterogeneity reveals personalized therapeutic strategies for patients with multiple myeloma
Avtorji:ID Kropivšek, Klara (Avtor)
ID Kachel, Paul (Avtor)
ID Goetze, Sandra (Avtor)
ID Wegmann, Rebekka (Avtor)
ID Festl, Yasmin (Avtor)
ID Severin, Yannik (Avtor)
ID Hale, Benjamin D. (Avtor)
ID Mena, Julien (Avtor)
ID Van Drogen, Audrey (Avtor)
ID Dietliker, Nadja (Avtor), et al.
Datoteke:URL https://www.nature.com/articles/s43018-023-00544-9
 
.pdf s43018-023-00544-9.pdf (10,16 MB)
MD5: E2F6E4CA36F8CF94419186DB65374071
 
URL https://www.nature.com/articles/s43018-023-00544-9.pdf
 
Jezik:Angleški jezik
Vrsta gradiva:Neznano
Tipologija:1.01 - Izvirni znanstveni članek
Organizacija:UNG - Univerza v Novi Gorici
Opis:Abstract Multiple myeloma (MM) is a plasma cell malignancy defined by complex genetics and extensive patient heterogeneity. Despite a growing arsenal of approved therapies, MM remains incurable and in need of guidelines to identify effective personalized treatments. Here, we survey the ex vivo drug and immunotherapy sensitivities across 101 bone marrow samples from 70 patients with MM using multiplexed immunofluorescence, automated microscopy and deep-learning-based single-cell phenotyping. Combined with sample-matched genetics, proteotyping and cytokine profiling, we map the molecular regulatory network of drug sensitivity, implicating the DNA repair pathway and EYA3 expression in proteasome inhibitor sensitivity and major histocompatibility complex class II expression in the response to elotuzumab. Globally, ex vivo drug sensitivity associated with bone marrow microenvironmental signatures reflecting treatment stage, clonality and inflammation. Furthermore, ex vivo drug sensitivity significantly stratified clinical treatment responses, including to immunotherapy. Taken together, our study provides molecular and actionable insights into diverse treatment strategies for patients with MM.
Ključne besede:ultiple myeloma, precision medicine, ex-vivo, pharmacoscopy, proteotyping, oncology, hematology, microscopy, drug score
Status publikacije:Objavljeno
Verzija publikacije:Objavljena publikacija
Datum objave:01.05.2023
Leto izida:2023
Št. strani:str. 734-753
Številčenje:Vol. 52, no. 5
PID:20.500.12556/RUNG-9465 Novo okno
COBISS.SI-ID:214560259 Novo okno
UDK:616-006
ISSN pri članku:2662-1347
eISSN:2662-1347
DOI:10.1038/s43018-023-00544-9 Novo okno
NUK URN:URN:SI:UNG:REP:TRKKULPQ
Datum objave v RUNG:11.11.2024
Število ogledov:646
Število prenosov:5
Metapodatki:XML DC-XML DC-RDF
:
KROPIVŠEK, Klara, KACHEL, Paul, GOETZE, Sandra, WEGMANN, Rebekka, FESTL, Yasmin, SEVERIN, Yannik, HALE, Benjamin D., MENA, Julien, VAN DROGEN, Audrey in DIETLIKER, Nadja, 2023, Ex vivo drug response heterogeneity reveals personalized therapeutic strategies for patients with multiple myeloma. Nature cancer [na spletu]. 2023. Vol. 52, no. 5, p. 734–753. [Dostopano 7 april 2025]. DOI 10.1038/s43018-023-00544-9. Pridobljeno s: https://repozitorij.ung.si/IzpisGradiva.php?lang=slv&id=9465
Kopiraj citat
  
Skupna ocena:
0.5
1
1.5
2
2.5
3
3.5
4
4.5
5
(0 glasov)
Vaša ocena:Ocenjevanje je dovoljeno samo prijavljenim uporabnikom.
Objavi na:Bookmark and Share


Postavite miškin kazalec na naslov za izpis povzetka. Klik na naslov izpiše podrobnosti ali sproži prenos.

Gradivo je del revije

Naslov:Nature cancer
Skrajšan naslov:Nat. cancer
Založnik:Nature Research
ISSN:2662-1347
COBISS.SI-ID:175636227 Novo okno

Licence

Licenca:CC BY 4.0, Creative Commons Priznanje avtorstva 4.0 Mednarodna
Povezava:http://creativecommons.org/licenses/by/4.0/deed.sl
Opis:To je standardna licenca Creative Commons, ki daje uporabnikom največ možnosti za nadaljnjo uporabo dela, pri čemer morajo navesti avtorja.
Začetek licenciranja:20.04.2023
Licenca:CC BY 4.0, Creative Commons Priznanje avtorstva 4.0 Mednarodna
Povezava:http://creativecommons.org/licenses/by/4.0/deed.sl
Opis:To je standardna licenca Creative Commons, ki daje uporabnikom največ možnosti za nadaljnjo uporabo dela, pri čemer morajo navesti avtorja.
Začetek licenciranja:20.04.2023

Nazaj